Cargando…

The Perception among Israeli Gastroenterologists Regarding Treatment of Patients with Biosimilar Medications

Background and Objectives: The ever-expanding entry of biosimilar drugs into the Israeli market requires doctors to decide whether to prescribe these medications. We aimed to assess the prevalence of biosimilar use and Israeli gastroenterologists’ knowledge, experience, and perception of biosimilar...

Descripción completa

Detalles Bibliográficos
Autores principales: Richter, Vered, Cohen, Daniel L., Bermont, Anton, Shalem, Tzippi, Broide, Efrat, Shirin, Haim
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10059953/
https://www.ncbi.nlm.nih.gov/pubmed/36984524
http://dx.doi.org/10.3390/medicina59030523
_version_ 1785016998720176128
author Richter, Vered
Cohen, Daniel L.
Bermont, Anton
Shalem, Tzippi
Broide, Efrat
Shirin, Haim
author_facet Richter, Vered
Cohen, Daniel L.
Bermont, Anton
Shalem, Tzippi
Broide, Efrat
Shirin, Haim
author_sort Richter, Vered
collection PubMed
description Background and Objectives: The ever-expanding entry of biosimilar drugs into the Israeli market requires doctors to decide whether to prescribe these medications. We aimed to assess the prevalence of biosimilar use and Israeli gastroenterologists’ knowledge, experience, and perception of biosimilar treatment. Materials and Methods: A cross-sectional survey was conducted among Israeli Gastroenterology Association (IGA) members between March and May 2022 using a structured 20-item questionnaire. Results: The questionnaire was completed by 108 gastroenterologists. Sixty-two percent prescribed biosimilars to their patients in the past year. Most of the patients (81%) were biologically naïve and only 19% were switched to a biosimilar. Most gastroenterologists (75%) answered that the effectiveness is the same. The rates of resistance to switching were 19%, 36%, and 70% for patients in remission for over two years, pregnant women, and difficulty reaching remission, respectively. In cases seeing a lack of response after switching, most physicians chose to change the mechanism of action, with only a small percentage returning to the brand-name drug. Conclusions: Most Israeli gastroenterologists are not concerned about biosimilars’ safety and efficacy. Despite this, most physicians will prefer the brand-name drug, especially regarding adalimumab. The populations in which physicians most oppose switching are those who have had difficulty achieving remission and pregnant women.
format Online
Article
Text
id pubmed-10059953
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-100599532023-03-30 The Perception among Israeli Gastroenterologists Regarding Treatment of Patients with Biosimilar Medications Richter, Vered Cohen, Daniel L. Bermont, Anton Shalem, Tzippi Broide, Efrat Shirin, Haim Medicina (Kaunas) Article Background and Objectives: The ever-expanding entry of biosimilar drugs into the Israeli market requires doctors to decide whether to prescribe these medications. We aimed to assess the prevalence of biosimilar use and Israeli gastroenterologists’ knowledge, experience, and perception of biosimilar treatment. Materials and Methods: A cross-sectional survey was conducted among Israeli Gastroenterology Association (IGA) members between March and May 2022 using a structured 20-item questionnaire. Results: The questionnaire was completed by 108 gastroenterologists. Sixty-two percent prescribed biosimilars to their patients in the past year. Most of the patients (81%) were biologically naïve and only 19% were switched to a biosimilar. Most gastroenterologists (75%) answered that the effectiveness is the same. The rates of resistance to switching were 19%, 36%, and 70% for patients in remission for over two years, pregnant women, and difficulty reaching remission, respectively. In cases seeing a lack of response after switching, most physicians chose to change the mechanism of action, with only a small percentage returning to the brand-name drug. Conclusions: Most Israeli gastroenterologists are not concerned about biosimilars’ safety and efficacy. Despite this, most physicians will prefer the brand-name drug, especially regarding adalimumab. The populations in which physicians most oppose switching are those who have had difficulty achieving remission and pregnant women. MDPI 2023-03-07 /pmc/articles/PMC10059953/ /pubmed/36984524 http://dx.doi.org/10.3390/medicina59030523 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Richter, Vered
Cohen, Daniel L.
Bermont, Anton
Shalem, Tzippi
Broide, Efrat
Shirin, Haim
The Perception among Israeli Gastroenterologists Regarding Treatment of Patients with Biosimilar Medications
title The Perception among Israeli Gastroenterologists Regarding Treatment of Patients with Biosimilar Medications
title_full The Perception among Israeli Gastroenterologists Regarding Treatment of Patients with Biosimilar Medications
title_fullStr The Perception among Israeli Gastroenterologists Regarding Treatment of Patients with Biosimilar Medications
title_full_unstemmed The Perception among Israeli Gastroenterologists Regarding Treatment of Patients with Biosimilar Medications
title_short The Perception among Israeli Gastroenterologists Regarding Treatment of Patients with Biosimilar Medications
title_sort perception among israeli gastroenterologists regarding treatment of patients with biosimilar medications
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10059953/
https://www.ncbi.nlm.nih.gov/pubmed/36984524
http://dx.doi.org/10.3390/medicina59030523
work_keys_str_mv AT richtervered theperceptionamongisraeligastroenterologistsregardingtreatmentofpatientswithbiosimilarmedications
AT cohendaniell theperceptionamongisraeligastroenterologistsregardingtreatmentofpatientswithbiosimilarmedications
AT bermontanton theperceptionamongisraeligastroenterologistsregardingtreatmentofpatientswithbiosimilarmedications
AT shalemtzippi theperceptionamongisraeligastroenterologistsregardingtreatmentofpatientswithbiosimilarmedications
AT broideefrat theperceptionamongisraeligastroenterologistsregardingtreatmentofpatientswithbiosimilarmedications
AT shirinhaim theperceptionamongisraeligastroenterologistsregardingtreatmentofpatientswithbiosimilarmedications
AT richtervered perceptionamongisraeligastroenterologistsregardingtreatmentofpatientswithbiosimilarmedications
AT cohendaniell perceptionamongisraeligastroenterologistsregardingtreatmentofpatientswithbiosimilarmedications
AT bermontanton perceptionamongisraeligastroenterologistsregardingtreatmentofpatientswithbiosimilarmedications
AT shalemtzippi perceptionamongisraeligastroenterologistsregardingtreatmentofpatientswithbiosimilarmedications
AT broideefrat perceptionamongisraeligastroenterologistsregardingtreatmentofpatientswithbiosimilarmedications
AT shirinhaim perceptionamongisraeligastroenterologistsregardingtreatmentofpatientswithbiosimilarmedications